EUVIMEDOpdag EUVIMED
Open access

Selective elimination of circulating effector CD8 T cells via LTβR blockade separates anti-CD137 efficacy from toxicity

Sergey A Shein iD, Anna A Korchagina iD, Li-Ju Wang iD, Zhao Lai, Yidong Chen iD, Jacob S Fisher iD, Burkhard Ludewig iD, Jessica N Lancaster iD, Yang-Xin Fu iD, Ekaterina Koroleva iD, Alexei V Tumanov iD

Science Advances · 2026-04-24 · 12 (17)

DOI: 10.1126/sciadv.aea8737 ↗

At a glance

Journal article in Science Advances, published on 2026-04-24. Written by Sergey A Shein and 10 co-authors. Institution: Department of Microbiology, Immunology, and Molecular Genetics, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA. Major MEDLINE topics: CD8-Positive T-Lymphocytes, Immunotherapy. 118 references. The full text is freely available in PubMed Central. Funded by: NIA NIH HHS, NINDS NIH HHS, NIH HHS.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

The major barrier to clinical translation of αCD137 immunotherapy is separating antitumor efficacy from hepatotoxicity driven by IFN-γ–producing CD8 T cells. We propose a strategy to limit toxicity by promoting contraction of excessively expanded CD8 T cells. We identify CD11c + KLRG1 + effector CD8 T cells (CD11c + T E ) as the primary source of IFN-γ, recirculating between blood and secondary lymphoid organs (SLOs), where they undergo apoptosis during contraction. We show that lymphotoxin β receptor (LTβR) signaling restrains this contraction. Mechanistically, lymphotoxin-expressing B cells activate LTβR in fibroblastic reticular cells (FRCs), suppressing apoptosis of CD11c + T E cells in the spleen and sustaining their systemic circulation and liver infiltration. Pharmacological LTβR blockade abrogates hepatotoxicity by reducing the accumulation of IFN-γ–producing CD11c + T E cells while preserving tumor-specific CD8 T cell responses. These findings identify LTβR as a key regulator of effector CD8 T cell persistence and support the use of LTβR antagonists to improve the safety of αCD137-based immunotherapy.

Subjects

MeSH terms (MEDLINE)

CD8-Positive T-LymphocytesImmunotherapyMaleFemaleAnimalsMiceMice, Inbred C57BLLymphotoxin beta ReceptorTumor Necrosis Factor Receptor Superfamily, Member 9Interferon-gammaSignal Transduction

Substances

Lymphotoxin beta ReceptorTumor Necrosis Factor Receptor Superfamily, Member 9Interferon-gamma

Authors and institutions

  • Department of Microbiology, Immunology, and Molecular Genetics, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.
  • Department of Molecular Medicine, UTHSCSA, San Antonio, TX, USA.
  • Greehey Children's Cancer Research Institute, San Antonio, TX, USA.
  • Department of Population Health Sciences, UTHSCSA, San Antonio, TX, USA.
  • Department of Immunology, Mayo Clinic, Phoenix, AZ, USA.
  • Institute of Immunobiology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.

ORCID profiles: Sergey A Shein, Anna A Korchagina, Li-Ju Wang, Yidong Chen, Jacob S Fisher, Burkhard Ludewig, Jessica N Lancaster, Yang-Xin Fu, Ekaterina Koroleva, Alexei V Tumanov

Funding

  • NIA NIH HHS
  • NINDS NIH HHS
  • NIH HHS
  • NCI NIH HHS
  • National Institutes of Health
  • National Institute on Aging
  • National Cancer Institute
  • National Institute of General Medical Sciences

Cite

APA

Shein, S. A., Korchagina, A. A., Wang, L. J., Lai, Z., Chen, Y., Fisher, J. S., Ludewig, B., Lancaster, J. N., Fu, Y. X., Koroleva, E., & Tumanov, A. V. (2026). Selective elimination of circulating effector CD8 T cells via LTβR blockade separates anti-CD137 efficacy from toxicity. Science Advances, 12(17). https://doi.org/10.1126/sciadv.aea8737

Vancouver

Shein SA, Korchagina AA, Wang LJ, Lai Z, Chen Y, Fisher JS, et al. Selective elimination of circulating effector CD8 T cells via LTβR blockade separates anti-CD137 efficacy from toxicity. Science Advances. 2026;12(17). doi:10.1126/sciadv.aea8737

BibTeX
@article{Shein2026,
  author = {Shein, Sergey A and Korchagina, Anna A and Wang, Li-Ju and Lai, Zhao and Chen, Yidong and Fisher, Jacob S and Ludewig, Burkhard and Lancaster, Jessica N and Fu, Yang-Xin and Koroleva, Ekaterina and Tumanov, Alexei V},
  title = {Selective elimination of circulating effector CD8 T cells via LTβR blockade separates anti-CD137 efficacy from toxicity},
  journal = {Science Advances},
  year = {2026},
  volume = {12},
  number = {17},
  doi = {10.1126/sciadv.aea8737}
}
Start for free →